0 CHECKOUT

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review

  • ID: 1322600
  • June 2016
  • 56 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Biodel Inc.
  • Depomed, Inc.
  • DURECT Corporation
  • MORE

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biodel Inc.
  • Depomed, Inc.
  • DURECT Corporation
  • MORE

List of Tables

List of Figures

Section 1 - About the Company

Flamel Technologies S.A. - Key Facts

Flamel Technologies S.A. - Key Employees

Flamel Technologies S.A. - Key Employee Biographies

Flamel Technologies S.A. - Major Products and Services

Flamel Technologies S.A. - Pharmaceutical Pipeline Products Data

Flamel Technologies S.A., Pipeline Products by Therapy Area

Flamel Technologies S.A., Pipeline Products by Development Phase

Flamel Technologies S.A. - History

Flamel Technologies S.A. - Company Statement

Flamel Technologies S.A. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 - Company Analysis

Flamel Technologies S.A. - Business Description

Flamel Technologies S.A. - Corporate Strategy

Flamel Technologies S.A. - SWOT Analysis

SWOT Analysis - Overview

Flamel Technologies S.A. - Strengths

Strength - Focused Research and Development Activities

Strength - Polymer-Based Drug Delivery Platforms

Strength - Lead Products

Flamel Technologies S.A. - Weaknesses

Weakness - Increased Credit Risk

Weakness - Complete Response Letter

Weakness - Dependence on Limited Customer Base

Flamel Technologies S.A. - Opportunities

Opportunity - Need for Novel Delivery Systems

Opportunity - New Product Approvals and Launches

Opportunity - Business Initiatives

Flamel Technologies S.A. - Threats

Threat - Uncertain R&D Outcomes

Threat - Intense Competition

Flamel Technologies S.A. - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Flamel Technologies S.A., Recent Deals Summary

Section 5 - Company’s Recent Developments

May 09, 2016: Flamel Technologies Reports First Quarter 2016 Results

Mar 10, 2016: Flamel Technologies Reports Fourth Quarter and Full Year 2015 Results

Jan 08, 2016: Flamel Technologies Provides Update on Corporate Progress

Nov 23, 2015: Flamel Technologies Appoints Michael Kanan Chief Financial Officer

Nov 12, 2015: Flamel Technologies Reports Third Quarter 2015 Results

Jul 30, 2015: Flamel Technologies Announces Second Quarter Results of Fiscal Year 2015

Jun 26, 2015: Flamel Technologies Appoints SVP of Quality and Regulatory Affairs and VP of Business and Corporate Development

May 15, 2015: Flamel Technologies Announces First Quarter Results of Fiscal Year 2015

Apr 07, 2015: Flamel Technologies Announces Departure of Senior Vice President of Business and Corporate Development

Mar 19, 2015: Flamel Technologies Announces Fourth Quarter and Full Year Results of Fiscal Year 2014

Section 6 - Appendix

Methodology

Ratio Definitions

About

Contact Us

Disclaimer

List of Tables

Flamel Technologies S.A., Key Facts

Flamel Technologies S.A., Key Employees

Flamel Technologies S.A., Key Employee Biographies

Flamel Technologies S.A., Major Products and Services

Flamel Technologies S.A., Number of Pipeline Products by Therapy Area

Flamel Technologies S.A., Number of Pipeline Products by Development Stage

Flamel Technologies S.A., Pipeline Products By Therapy Area and Development Phase

Flamel Technologies S.A., History

Flamel Technologies S.A., Subsidiaries

Flamel Technologies S.A., Key Competitors

Flamel Technologies S.A., Ratios based on current share price

Flamel Technologies S.A., Annual Ratios

Flamel Technologies S.A., Interim Ratios

Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016

Flamel Technologies S.A., Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

Flamel Technologies S.A., Pipeline Products by Therapy Area

Flamel Technologies S.A., Pipeline Products by Development Phase

Flamel Technologies S.A., Performance Chart (2011 - 2015)

Flamel Technologies S.A., Ratio Charts

Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016

Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

Note: Product cover images may vary from those shown
3 of 4

Veloxis Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc.
DURECT Corporation
Depomed, Inc.
Biodel Inc.
Acura Pharmaceuticals, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.